

1   **Concurrent Resolution Directing PEHP Regarding Hormone Replacement Therapy**

2026 GENERAL SESSION

STATE OF UTAH

**Chief Sponsor: Karianne Lisonbee**

Senate Sponsor:

---

---

2   **LONG TITLE**

3   **General Description:**

4       This resolution directs the Public Employees' Benefit and Insurance Program to provide  
5       hormone replacement therapy for menopausal symptoms.

6   **Highlighted Provisions:**

7       This resolution:

8           ▸ recognizes that hormone replacement therapy is a safe and effective treatment for  
9       menopausal symptoms; and

10           ▸ directs the Public Employees' Benefit and Insurance Program to provide hormone  
11       replacement therapy for menopausal symptoms.

12   **Money Appropriated in this Bill:**

13       None

14   **Other Special Clauses:**

15       None

---

---

16       *Be it resolved by the Legislature of the state of Utah, the Governor concurring therein:*

17       WHEREAS, in accordance with Section 49-20-201, the state participates in the Public  
18       Employees' Benefit and Insurance Program (PEHP);

19       WHEREAS, menopause is a natural phase of aging when a woman has gone 12 consecutive  
20       months without a menstrual period due to a decline in reproductive hormones;

21       WHEREAS, menopause can cause a variety of symptoms including irregular periods, hot  
22       flashes, night sweats, vaginal dryness, urinary urgency, difficulty sleeping, emotional changes,  
23       dry skin, worsening premenstrual syndrome, and breast tenderness;

24       WHEREAS, many menopausal women face barriers accessing effective treatment due to a  
25       range of factors including healthcare provider knowledge gaps, stigma, and lack of readily  
26       available menopause specialists;

27       WHEREAS, recent studies have shown that hormone replacement therapy (HRT) has a low  
28       risk of adverse events and is a safe treatment for menopausal symptoms;

31        WHEREAS, FDA-approved HRT treatments can restore estrogen and progesterone, which  
32        naturally decline as women go through menopause;

33        WHEREAS, in November of 2025, the U.S. Department of Health and Human Services  
34        announced that the U.S. Food and Drug Administration was initiating the removal of broad  
35        "black box" warnings from HRT treatments for menopause:

36        NOW, THEREFORE, BE IT RESOLVED that the Legislature of the state of Utah, the  
37        Governor concurring therein, directs PEHP for state employees to include in PEHP's drug  
38        formulary HRT treatments to relieve menopausal symptoms.

39        BE IT FURTHER RESOLVED that a copy of this resolution be sent to the Public  
40        Employees' Benefit and Insurance Program.